The University College London (UCL) sponsored study evaluates safety, tolerability and radiation dosimetry of an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical therapy, building on Blue Earth Therapeutics’ radiohybrid platform. For Media and Investors only OXFORD,…
Source: prnewswire
Country: United States